Sight Sciences, Inc. (SGHT) Stock Price & Analysis
Sight Sciences, Inc. (SGHT) rose 4.47% to USD 4.91 as of July 25, 2026 at 03:03 UTC, according to Nexqual real-time market data.
SGHT last closed at USD 4.7; the session ranged USD 4.65–4.94 on volume of 139,321 shares. Market capitalization is $267.15M, with a 52-week range of USD 3.11–9.24 (NMS). Source: Nexqual, July 25, 2026 at 03:03 UTC.
Key Statistics (as of July 25, 2026 at 03:03 UTC)
| Price | USD 4.91 |
|---|---|
| Change | ▲ 4.47% (up) |
| Previous Close | USD 4.7 |
| Open | USD 4.76 |
| Day Range | USD 4.65 – 4.94 |
| 52-Week Range | USD 3.11 – 9.24 |
| Volume | 139,321 shares |
| Market Cap | $267.15M |
| Exchange | NMS |
Technical Analysis (SGHT)
Nexqual's technical model rates SGHT "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 03:03 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 47.7 (neutral) |
| vs SMA50 | Below (USD 5.06) |
| MACD | -0.06 (negative) |
Analyst Ratings (SGHT)
Wall Street analysts rate SGHT "None" based on 4 analysts, with a mean price target of USD 8.75 (range USD 6–12), per Nexqual as of July 25, 2026 at 03:03 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 8.75 |
| High Target | USD 12 |
| Low Target | USD 6 |
| Buy / Hold / Sell | 4 / 2 / 0 |
Earnings (SGHT)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD -0.17 |
| Revenue Estimate | $21.69M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.24 vs est -0.2 ▼ miss |
| 2025-12-31 | USD -0.08 vs est -0.14 ▲ beat |
| 2025-09-30 | USD -0.16 vs est -0.26 ▲ beat |
| 2025-06-30 | USD -0.23 vs est -0.28 ▲ beat |
Source: Nexqual, July 25, 2026 at 03:03 UTC.
Financials & Fundamentals (SGHT)
| Total Revenue | $79.55M |
|---|---|
| Revenue Growth (YoY) | +12.50% |
| Gross Margin | +86.17% |
| Operating Margin | -35.60% |
| Profit Margin | -46.83% |
| ROE | -56.64% |
| Debt / Equity | 77.47 |
| Current Ratio | 5.86 |
| Total Cash | $84.96M |
| Total Debt | $41.76M |
| Free Cash Flow | $-8.58M |
Source: Nexqual, July 25, 2026 at 03:03 UTC.
Financial Health Score (SGHT)
Nexqual rates Sight Sciences, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 03:03 UTC.
| Growth | Weak — Revenue -3% YoY (annual), declining |
|---|---|
| Profitability | Solid — Gross margin 86%, operating -36% |
| Balance Sheet | Mixed — $85M cash vs $42M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$9M, burning cash |
| Efficiency | Critical — ROE -57%, ROA -14.3% |
Ownership (SGHT)
| Insider Ownership | +19.98% |
|---|---|
| Institutional Ownership | +53.59% |
| Shares Outstanding | 54.41M |
| Float | 35.12M |
| Short % of Float | +1.84% |
Source: Nexqual, July 25, 2026 at 03:03 UTC.
Leadership (SGHT)
Sight Sciences, Inc. is led by Paul Badawi (age 49), Co-Founder, President, CEO & Director, per Nexqual as of July 25, 2026 at 03:03 UTC.
| Co-Founder, President, CEO & Director | Paul Badawi (age 49) |
|---|---|
| Chief Operating Officer | Alison Perry Bauerlein (age 44) |
| Co-Founder, CTO & Director | David Badawi (age 54) |
| CFO & Treasurer | James Rodberg (age 41) |
Major Backers & Investors (SGHT)
Notable institutional backers of Sight Sciences, Inc. include KCK LTD., Long Focus Capital Management, LLC, Pathstone Holdings, LLC, according to Nexqual as of July 25, 2026 at 03:03 UTC.
Active Investors
| Investor | Stake |
|---|---|
| KCK LTD. | 8.04% |
| Long Focus Capital Management, LLC | 6.61% |
| Pathstone Holdings, LLC | 4.41% |
| Americana Partners, LLC | 3.09% |
| B Group, Inc. | 1.78% |
| Acadian Asset Management. LLC | 1.42% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.24% |
| Vanguard Group | 5.66% |
| Geode Capital | 1.68% |
| State Street | 1.53% |
Source: Nexqual, July 25, 2026 at 03:03 UTC.
From Sight Sciences, Inc.'s Latest SEC 10-K Filing (filed 2026-03-04)
Key Strengths & Strategy (as disclosed to the SEC)
- Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States.
- The company operates in two segments, Surgical Glaucoma and Dry Eye.
- It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology.
- It serves hospitals, medical centers, and eyecare professionals through sales representatives and distributors.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CTKB | Cytek Biosciences, Inc. | USD 4.46 | ▼ 1.76% |
| TMCI | Treace Medical Concepts, Inc. | USD 4 | ▲ 0.76% |
| RPID | Rapid Micro Biosystems, Inc. | USD 1.99 | ▼ 3.4% |
| RXST | RxSight, Inc. | USD 5.19 | ▼ 3.71% |
| DSGN | Design Therapeutics, Inc. | USD 11.78 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:03 UTC. This page is informational and not investment advice.